Top Page
Optimi Health
(OPTI)
Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)
Optimi Health Business Overview & Revenue Model
Optimi Health Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 426.30K | 389.85K | 181.09K | 80.72K | 0.00 |
| Gross Profit | -2.07M | 270.91K | -157.04K | 53.92K | -47.12K |
| EBITDA | -2.23M | -4.74M | -4.42M | -7.03M | -5.95M |
| Net Income | -3.71M | -6.04M | -5.19M | -7.38M | -6.04M |
Balance Sheet | |||||
| Total Assets | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15M | 103.66K | 1.34M | 1.89M | 12.43M |
| Total Debt | 6.68M | 2.75M | 1.71M | 157.58K | 250.84K |
| Total Liabilities | 8.64M | 4.98M | 3.28M | 797.66K | 2.40M |
| Stockholders Equity | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
Cash Flow | |||||
| Free Cash Flow | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
| Operating Cash Flow | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Investing Cash Flow | -88.38K | -154.02K | -706.02K | -3.15M | -9.19M |
| Financing Cash Flow | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
Optimi Health Technical Analysis
Optimi Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$32.58M | 3.70 | 7.78% | ― | 28.55% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$13.08M | 5.19 | ― | ― | 15.64% | 58.47% | |
46 Neutral | C$20.11M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
44 Neutral | C$28.07M | -4.90 | -57.28% | ― | 65.16% | 33.18% | |
42 Neutral | C$13.19M | -4.62 | 75.85% | ― | 95.76% | 22.56% |
Optimi Health Corporate Events
Optimi Health plans to pursue a listing on the Nasdaq Capital Market under the ticker “OPTH” alongside an underwritten public offering of common shares in the United States. The company has filed a registration statement with the U.S. Securities and Exchange Commission, and Joseph Gunnar & Co. is acting as sole book-running manager for the planned U.S. offering.
To meet Nasdaq’s minimum share price requirements, Optimi’s board has approved a 30-for-1 share consolidation to be effected prior to the registration statement becoming effective. The consolidation will reduce the company’s outstanding shares from about 96.8 million to roughly 3.2 million while maintaining shareholders’ proportional ownership, and is expected to support the company’s efforts to broaden its investor base and enhance its visibility in U.S. capital markets.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.29 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has begun early clinical rollout of its naturally derived 5 mg psilocybin capsules for patients with treatment-resistant depression in Australia, marking the first patients of 2026 treated outside sponsor-led clinical trials under the country’s regulated framework. The products are manufactured in Canada to TGA quality standards and supplied via an Australian pharmacy partner, with administration handled by Authorised Prescribers under national rules.
The company is now supplying both psilocybin for depression and MDMA for PTSD into Australia’s regulated medical framework, signalling growing clinical adoption of psychedelic therapies within the Authorised Prescriber Scheme. Treatment data and patient-reported outcomes are being captured in a national registry in partnership with Australian National University, underscoring a structured, data-driven approach that may influence future policy, clinical practice, and broader market acceptance of psychedelic-assisted therapies.
The most recent analyst rating on (TSE:OPTI) stock is a Sell with a C$0.28 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has completed the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for use in patients with treatment-resistant depression under the country’s Authorised Prescriber Scheme. This marks the company’s second psychedelic drug product in the Australian market, joining its 40 mg and 60 mg MDMA capsules for PTSD, and underscores its fully integrated production model and growing role in regulated psychedelic-assisted therapy.
The new psilocybin capsules will be available through authorised clinics, including programs that may be reimbursed by Australia’s Department of Veterans’ Affairs, potentially broadening patient access and supporting real-world data collection through a national patient registry with the Australian National University. By leveraging its Drug Establishment Licence to export pharmaceutical-grade products internationally, Optimi strengthens its position in the emerging medical psychedelics sector and deepens its commercial foothold in Australia’s regulated therapeutic framework.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.36 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has begun the first MDMA-assisted treatments of 2026 at an expanded network of authorized clinics in Australia, under the country’s Authorised Prescriber Scheme. The company is supplying its 40 mg and 60 mg MDMA capsules directly to clinics, maintaining manufacturing oversight and cost control while supporting a scalable model for regulated psychedelic therapy.
The rollout aligns with growing institutional support in Australia, including a veterans rehabilitation plan that backs psychedelic-assisted therapy for PTSD. With real-world evidence on patient outcomes being collected by the Australian National University and no serious adverse events reported in Scheme data as of late 2025, the initiative strengthens Optimi’s position in the emerging market for MDMA-assisted PTSD treatment, particularly among veterans and first responders.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has completed its first MDMA export of 2026 to Australia, shipping 1,000 standardized 60 mg capsules for use in authorized clinical programs treating Post-Traumatic Stress Disorder under the country’s Authorised Prescriber Scheme. The batch, sufficient for more than 300 MDMA-assisted therapy sessions, strengthens Optimi’s role in Australia’s emerging psychedelic treatment market and supports extensive real-world evidence gathering by the Australian National University, while its Australian pharmacy partner distributes the product to clinics nationwide under existing reimbursement and regulatory frameworks aimed at veterans and other PTSD patients.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has completed its first 2026 production cycle of MDMA and psilocybin capsules for the Australian market, with 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) now fully packaged, labeled and batch-released under its Health Canada Drug Establishment Licence. Following issuance of Australian import permits, the GMP-compliant capsules have been approved for import under Australia’s Authorised Prescriber Scheme, positioning Optimi to continue and potentially expand supply into the country’s regulated healthcare system at a time when PTSD and treatment-resistant depression remain significant unmet medical needs affecting millions of Australians.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health has approved an equity incentive grant comprising 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals, with the aim of aligning compensation with long-term growth and retention objectives. The company has also engaged Diamond Equity Research for independent research coverage and Native Ads for a digital investor awareness campaign of up to US$350,000 over as long as 24 months, moves intended to broaden market visibility for its regulated MDMA and psilocybin product portfolio and potentially strengthen its positioning among investors in the emerging psychedelic pharmaceuticals sector.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Optimi Health Corp. will present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026, where CEO Dane Stevens is scheduled to host a virtual presentation and one-on-one meetings with institutional investors. By engaging directly with the investment community at a dedicated micro-cap forum, the company is seeking to raise its profile among institutional investors and potentially broaden its shareholder base as it advances its position in the emerging market for regulated psychedelic-based mental health treatments.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.